Key result
The APOEε4 polymorphism was not associated with an increased risk of aneurysmal subarachnoid haemorrhage, the occurrence of early cerebral vasospasm, or worse 1-year neurological outcome.
Why the study?
Does the APOEε4 polymorphism influence the risk of aSAH, cerebral vasospasm, or 1-year neurological outcome?
Population
147 patients with aneurysmal subarachnoid haemorrhage (aSAH) and 211 gender- and area-matched healthy controls
Comparison
Presence of APOEε4 polymorphism vs Absence of APOEε4 polymorphism (non-APOEε4)
Design
Cohort, blinded
Follow-up
1 year
Authors
Loading...
APOEε4 not linked to aSAH risk or outcomes in this cohort; leaves open its prognostic role pending larger studies.
Observational (n=358)
Blinded
Does the APOEε4 polymorphism influence the risk of aSAH, cerebral vasospasm, or 1-year neurological outcome?
The APOEε4 polymorphism does not appear to influence the risk of developing aneurysmal subarachnoid hemorrhage, subsequent cerebral vasospasm, or long-term neurological outcomes.
Csajbok et al. (2015) conducted an observational in Aneurysmal subarachnoid haemorrhage (aSAH) (n=358). APOEε4 polymorphism vs. Non-APOEε4 allele / healthy individuals was evaluated on Risk of aSAH, risk of early cerebral vasospasm, and 1-year neurological outcome. The APOEε4 polymorphism was not associated with an increased risk of aneurysmal subarachnoid haemorrhage, the occurrence of early cerebral vasospasm, or worse 1-year neurological outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: